NewsTRANSPLANTATION AND CELLULAR THERAPYWednesday, April 8, 2026 · April 8, 2026
Belumosudil for Chronic Graft-Versus-Host Disease: A Systematic Review and Meta-Analysis.
WHY IT MATTERS
Recent peer-reviewed research on Chronic graft versus host disease that may be relevant for patients and caregivers.
Chronic graft-versus-host disease (cGvHD) is a debilitating complication following allogeneic hematopoietic stem cell transplantation, often refractory to standard therapies. Belumosudil, a selective ROCK2 inhibitor with immunomodulatory and antifibrotic properties, has emerged as a targeted treatme...
Related conditions
Related news
Int J Circumpolar Health · -250 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.…
Ther Adv Rare Dis · -220 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.…
Health Inf Sci Syst · -220 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.…
Mol Ther Nucleic Acids · -52 days ago
The post-pandemic pivot: mRNA therapeutics enter the chronic rare disease arena
Published in Mol Ther Nucleic Acids. Giangrande PH et al.…